RAPP

Rapport Therapeutics, Inc. (RAPP) - Q3 2024 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system (CNS) disorders using its RAP technology platform. The company's lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator being developed for focal epilepsy, bipolar disorder, and diabetic peripheral neuropathic pain (DPNP). In June 2024, the company completed its Initial Public Offering (IPO) and a concurrent private placement.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses for the nine months ended September 30, 2024, increased by $38.1 million compared to the same period in 2023. This was driven by a $27.5 million increase in R&D expenses (due to Phase 2a trial start-up costs, toxicology studies, and manufacturing) and a $10.6 million increase in G&A expenses (due to headcount growth and public company compliance costs).
• Significant Interest Income: Interest income rose to $8.6 million for the nine months ended September 30, 2024, compared to $1.2 million in the prior year period, reflecting higher cash balances from the IPO and Series B financing.
• One-Time Liability Adjustment: The nine-month 2024 results included a $7.4 million expense related to the change in fair value of the Series B preferred stock tranche right liability prior to its settlement in March 2024. This item is not expected to recur.
• Capital Structure: Following the June 2024 IPO, all Series A and Series B convertible preferred stock was converted to common stock. The company raised net proceeds of approximately $157.6 million from the IPO and private placement.

Guidance, Outlook, and Risks

• Clinical Progress: Patient recruitment is underway for the Phase 2a proof-of-concept trial of RAP-219 in focal epilepsy, with topline results expected in mid-2025. A second Multiple Ascending Dose (MAD) trial is expected to complete by the end of 2024.
• Regulatory Hold: The FDA placed a clinical hold on the Investigational New Drug (IND) application for the Phase 2a trial of RAP-219 for diabetic peripheral neuropathic pain (DPNP). The hold is specific to the DPNP protocol design and does not impact the focal epilepsy or bipolar disorder programs. Management expects to resolve this hold.
• Liquidity: As of September 30, 2024, the company held $320.7 million in cash, cash equivalents, and short-term investments. Management believes these resources are sufficient to fund operations through the end of 2026.
• Key Risks: Risks include the uncertainty of clinical trial outcomes, the potential for the DPNP clinical hold to delay development, the need for additional capital in the future, and dependence on third-party manufacturers and CROs.

Investor Verification Checklist

• Resolution of FDA Clinical Hold: Verify the timeline and status of the FDA's clinical hold on the DPNP IND application.
• Cash Burn Rate: Monitor quarterly operating expenses to ensure the projected runway through 2026 remains accurate given the increased burn rate post-IPO.
• Phase 2a Enrollment: Track patient enrollment rates for the focal epilepsy trial to ensure the mid-2025 topline data date is achievable.
• Intellectual Property: Review the status of the Janssen license agreement and any potential milestone payment obligations.
• Stock-Based Compensation: Assess the impact of future equity grants on dilution and operating expenses.